The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Antidepressant-induced jitteriness/anxiety syndrome: systematic review
Open accessAbstract
Background: Early worsening of anxiety, agitation and irritability are thought to be common among people commencing antidepressants, especially for anxiety disorders. This phenomenon, which may be termed jitteriness/anxiety syndrome, is cited as an explanation for early treatment failure and caution in using selective serotonin reuptake inhibitors (SSRIs). However, we believe that it is inconsistently defined and that robust evidence to support the phenomenon is lacking. Aims: To review systematically all evidence relating to jitteriness/ anxiety syndrome to identify: constituent symptoms; medications implicated; disorders in which it was reported; incidence; time course; management strategies; relationship of this syndrome to therapeutic response; distinction between syndrome and akathisia; relationship between syndrome and suicide; and genetic predispositions. Method: A systematic search identified articles and these were included in the review if they addressed one of the above aspects of jitteriness/anxiety syndrome. Results: Of 245 articles identified, 107 articles were included for review. No validated rating scales for jitteriness/anxiety syndrome were identified. There was no robust evidence that the incidence differed between SSRIs and tricyclic antidepressants, or that there was a higher incidence in anxiety disorders. Published incidence rates varied widely from 4 to 65% of people commencing antidepressant treatment. Common treatment strategies for this syndrome included a slower titration of antidepressant and the addition of benzodiazepines. Conclusive evidence for the efficacy of these strategies is lacking. There was conflicting and inconclusive evidence as to whether the emergence of this syndrome had a predictive value on the response to treatment. It appears to be a separate syndrome from akathisia, but evidence for this assertion was limited. The effect of jitteriness/anxiety syndrome on suicide rates has not been evaluated. Three studies examined genetic variations and side-effects from treatment, but none was specifically designed to assess jitteriness/anxiety syndrome. Conclusions: Jitteriness/anxiety syndrome remains poorly characterised. Despite this, clinicians' perception of this syndrome influences prescribing and it is cited to support postulated mechanisms of drug action. We recommend systematised evaluation of side-effects at earlier time points in antidepressant trials to further elucidate this clinically important syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Suicide Risk During Antidepressant Treatment
Simon, G. E., Savarino, J., Operskalski, B., & Wang, P. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.41 · Cited by 424
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Tanskanen, A., & Haukka, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.12.1358 · Cited by 277
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235 · cited 3×
“Hu et al 37 conducted a retrospective telephone survey of patients taking SSRIs for over 3 months, assessing if side-effects began within 2 weeks and whether these persisted beyond 3 months.”
Gibbons, R. D., Brown, C. H., Hur, K., Marcus, S. M., Bhaumik, D. K., & Mann, J. J. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1044 · Cited by 167
24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder
Volkers, A. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00019-6 · Cited by 56
A dose-finding and discontinuation study of clomipramine in panic disorder
Lotufo-Neto, F., Bernik, M., Ramos, R. T., Andrade, L., Gorenstein, C., Cordás, T., Melo, M., & Gentil, V. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500103 · Cited by 27
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Self-citationPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Sehonova, P., Svobodova, Z., Dolezelova, P., Vosmerova, P., & Faggio, C. (2018) · Science of The Total Environment · doi:10.1016/j.scitotenv.2018.03.076 · Cited by 278
Activity of Raphé serotonergic neurons controls emotional behaviors
Teissier, A., Chemiakine, A., Inbar, B., Bagchi, S., Ray, R. S., Palmiter, R. D., Dymecki, S. M., Moore, H., & Ansorge, M. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.061 · Cited by 197
Ziegler, C., Richter, J., Mahr, M., Gajewska, A., Schiele, M. A., Gehrmann, A., Schmidt, B., Lesch, K.-P., Lang, T., Helbig-Lang, S., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.41 · Cited by 183
Metadata
- Authors
- Sinclair, L. I., Christmas, D. M., Hood, S. D., Potokar, J. P., Robertson, A., Isaac, A., Srivastava, S., Nutt, D. J., & Davies, S. J. C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2009-06
- Volume
- 194
- Issue
- 6
- Pages
- 483-490
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2161024131
- Cited by
- 181
- References
- 7
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.